New clinical trial explores targeted therapy for three types of rare and aggressive lymphoma

lymphoma cells

Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading a study to determine if pembrolizumab can improve outcomes for patients with certain rare lymphomas such as large B cell lymphoma, shown here. 
Photo credit: Google Images

Lymphoma arises in parts of the immune system where lymphocytes, a type of white blood cell, are produced. This type of cancer develops when lymphocytes start multiplying abnormally. A newly opened clinical trial led by Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is seeking to determine if pembrolizumab can improve outcomes for patients with certain rare lymphomas.  The study focuses mainly on three types of rare and aggressive lymphoma: gray-zone lymphoma, central nervous system lymphoma and extra-nodal diffuse large B-cell lymphomas. These lymphomas are often resistant to treatment with radiation and standard chemotherapy; however, they share a genetic feature that may make them responsive to targeted therapy. 

For more information about this trial, please visit: https://ccr.cancer.gov/Lymphoid-Malignancies-Branch/mark-j-roschewski.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow by treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. Search all CCR clinical trials, and subscribe to have the latest CCR clinical trials sent to your inbox.

Summary Posted: 11/2017